Close Menu
April 27, 2021
Sponsored by
Biognosys

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

GenomeWebinar

Medical Oncologist,
Gustave Roussy Institute

Scientific Project Manager,
Biognosys 

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Recent advances in mass spectrometry-based proteomics have fostered a more precise, deep, and more functional look into clinical phenotypes. Going beyond traditional genomics, proteomics enables more relevant, quantitative, and informative understanding of diseases and treatments.

Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, will share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.

They will discuss the results of a joint project in which serum from a cohort of patients infected with COVID-19 was submitted for analysis using the Biognosys HRM discovery proteomics platform. They will share details of proteomic profiles associated with clinical outcome, comorbidities, and the response to anti-IL6 treatment, which provide a comprehensive picture of the potential of using next-generation proteomics to enhance personalized medicine. 

About The Series: Next-Generation Proteomics for Precision Oncology

This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.

Sponsored by

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Apr
28
Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.